WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC® ON THE LEAD COMPOUND, TTX (HALNEURON®) September 25, 2023 Read more
WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION ON HALNEURON® AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC® September 12, 2023 Read more
News Brief: WEX Pharmaceuticals Inc. Announces Addition Of Intellectual Property For Its Novel Development And Use Of Tetrodotoxin (TTX) To Relieve Pain August 22, 2023 Read more
News Brief: WEX Pharmaceuticals Inc. Enrolls In Korea As Part Of The Multinational Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain March 21, 2023 Read more
News Brief: WEX Pharmaceuticals Inc. Enrolls The First Patient In The Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain January 3, 2023 Read more
